Advertisement

Topics

PubMed Journals Articles About "Thermography Golimumab Psoriatic Arthritis" RSS

05:15 EDT 19th September 2018 | BioPortfolio

Thermography Golimumab Psoriatic Arthritis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Thermography Golimumab Psoriatic Arthritis articles that have been published worldwide.

More Information about "Thermography Golimumab Psoriatic Arthritis" on BioPortfolio

We have published hundreds of Thermography Golimumab Psoriatic Arthritis news stories on BioPortfolio along with dozens of Thermography Golimumab Psoriatic Arthritis Clinical Trials and PubMed Articles about Thermography Golimumab Psoriatic Arthritis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Thermography Golimumab Psoriatic Arthritis Companies in our database. You can also find out about relevant Thermography Golimumab Psoriatic Arthritis Drugs and Medications on this site too.

Showing "Thermography Golimumab Psoriatic Arthritis" PubMed Articles 1–25 of 1,200+

Identification of a Single Nucleotide Polymorphism in NFKBIA with Different Effects on Psoriatic Arthritis and Cutaneous Psoriasis in China.

Genome-wide association studies have recently identified a number of non-major histocompatibility complex regions associated with psoriatic arthritis. However, data on Chinese patients with psoriatic arthritis and the differences between psoriatic arthritis and cutaneous psoriasis are limited. This study genotyped 12 single nucleotide polymorphisms in 379 patients with psoriatic arthritis, 376 with cutaneous psoriasis, and 760 healthy controls using Sequenom's Mass ARRAY system. The aim of the study was to ...


Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the tre...

"STATus of STAT3 in Psoriatic Arthritis."

Joint disease and enthesopathy are seen in about one-third of patients with psoriasis and are usually preceded by the cutaneous manifestations of psoriasis. The relationships between the pathogenesis of psoriatic skin disease and the pathogenesis of psoriatic arthritis have not been defined, however, and the central question as to whether psoriatic skin disease initiates development of joint disease remains unresolved. This article is protected by copyright. All rights reserved.


The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy.

The GO-DACT is an investigator-initiated, national, multicentric randomized placebo-controlled double-blinded trial, that assesses dactylitis as primary endpoint. Psoriatic arthritis patients naïve to methotrexate and biologic disease modifying anti-rheumatic drugs, with at least one active dactylitis, were assigned to golimumab in combination with methotrexate or placebo in combination with methotrexate, for 24 weeks. Both clinical (dactylitis severity score and the Leeds dactylitis index) and imaging (hi...

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials.

To evaluate ixekizumab safety in adults with psoriatic arthritis (PsA).

Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan.

Golimumab has been proven as an effective treatment for rheumatoid arthritis in clinical trials. However, there is a scarcity of data regarding its use in elderly patients in a real-world setting. This study aims to evaluate the safety, effectiveness, and treatment persistence of golimumab in elderly Japanese patients (≥ 75 years) with rheumatoid arthritis.

Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis.

To introduce a novel pre-clinical animal model of psoriatic arthritis, R26STAT3CCD4Cre mice, and investigate the role of Th17 cytokines in the disease pathogenesis.

Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis.

We aimed to determine the agreement between rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP in patients with psoriatic arthritis (PsA) and predictive value of IBP in identifying axial involvement in PsA.

Is ustekinumab effective for psoriatic arthritis with insufficient response to initial treatment?

Psoriatic arthritis is an inflammatory arthritis without a clear etiology. Biological therapy is key for its treatment, especially in more complex patients. There are several alternatives for biological treatment, but due to its high cost, it is important to evaluate their real effectiveness.

Comprehensive evaluation of finger flexor tendon entheseal soft tissue and bone changes by ultrasound can differentiate psoriatic arthritis and rheumatoid arthritis.

To determine whether a detailed sonographic evaluation of the hand flexor tendon compartment could help differentiate between psoriatic arthritis (PsA) and rheumatoid arthritis (RA).

Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?

To highlight the recently approved therapeutic agents in psoriatic arthritis (PsA), drugs in the pipeline, as well as to discuss efficacy with regard to different clinical domains of PsA.

Ustekinumab for the treatment of psoriasis and psoriatic arthritis: A drug evaluation and literature review.

Psoriasis is an autoimmune, inflammatory disorder characterized by proliferation of keratinocytes, and it may be associated with a systemic inflammatory articular disorder, psoriatic arthritis. The presentations of psoriasis and psoriatic arthritis are heterogeneous, and our understanding of the underlying pathogenesis has led to a better understanding of the vital role of the IL-23/Th17 immune axis. Areas covered: Ustekinumab is a monoclonal antibody against IL-12 and IL-23, and this review will focus on i...

Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study.

To study the prognostic value of widespread pain and of musculoskeletal ultrasound (US) examination for subsequent treatment outcomes in patients with psoriatic arthritis (PsA).

Real-world burden of comorbidities in US patients with psoriatic arthritis.

We assessed comorbidities associated with psoriatic arthritis in a broad cohort of US-insured adult patients using the Truven Health Analytics MarketScan Database.

Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Meta-analysis.

Fatigue is a significant issue in psoriatic arthritis. The objective was to assess the effect of biological disease modifying antirheumatic drugs and apremilast on fatigue in psoriatic arthritis randomised controlled trials and to compare this effect with the effect in the same trials, on pain, through a systematic literature review and meta-analysis.

Burden of Psoriatic Arthritis in different definitions of disease activity: comparing Minimal Disease Activity and Disease Activity index for Psoriatic Arthritis.

Treat-to-target strategies have improved outcomes in rheumatic diseases. In psoriatic arthritis (PsA), the proposed targets are the multidimensional target Minimal Disease Activity (MDA) and the articular target Disease Activity index for PsA (DAPSA). We aimed to compare burden of PsA in patients with low disease activity according to the two definitions MDA and DAPSA-Low Disease Activity (DAPSA-LDA), one year after diagnosis.

Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: A population-based study.

To estimate the prevalence and incidence of psoriasis and psoriatic arthritis (PsA) over time in Ontario, Canada.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with psoriasis have been reported.

Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.

In patients with psoriatic arthritis (PsA), limited data exist regarding patterns of biologic therapy use.

Early psoriatic arthritis in psoriatic patients: risk factors and screening for rheumatological evaluation.

Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data.

Psoriatic arthritis (PsA) is associated with multiple comorbid conditions, including cardiovascular (CV) comorbidities that impose a considerable burden on patients. Effective management of PsA requires an understanding of comorbidity profiles.

Management of Psoriatic Arthritis: Turkish League Against Rheumatism (TLAR) Expert Opinions.

This study aims to establish the first national treatment recommendations by the Turkish League Against Rheumatism (TLAR) for psoriatic arthritis (PsA) based on the current evidence.

Incidence and Predictive Factors for Orthopedic Surgery in Patients with Psoriatic Arthritis.

To investigate the incidence of orthopedic procedures in patients with psoriatic arthritis (PsA), and how patient characteristics, time of diagnosis, and treatment affect the need for surgery.

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.

For patients with rheumatoid arthritis (RA) who do not respond or lose response to anti-tumor necrosis factor (TNF) biologics, switching to a different anti-TNF can be an effective means to manage symptoms and disease progression. This study examined the utilization and effectiveness of intravenous golimumab within a real-world population of patients with RA switching directly from infliximab, a potent anti-TNF.

Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

The primary objective of this study was to compare the risk of major cardiovascular events (MACE) in a large observational cohort of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) patients METHODS: We conducted a mixed retrospective and prospective cohort study using data from patients with RA, PsA and axSpA included in the Swiss Clinical Quality Management registry. The primary outcome of interest was a composite of myocardial infarction, transient or permanent cer...


Advertisement
Quick Search
Advertisement
Advertisement